Scott K. Durum
Senior Investigator
Center for Cancer Research
National Cancer Institute
United States of America
Biography
After receiving his Ph.D. in 1978, Dr. Durum received his postdoctoral training in immunology at the National Jewish Hospital in Denver and at Yale Medical School. Dr. Durum joined the Laboratory of Molecular Immunoregulation in 1984.
Research Interest
interleukin-7 (IL-7), immunity, leukemogenesis
Publications
-
McLean MH, Neurath MF, Durum SK. Targeting interleukins for the treatment of inflammatory bowel disease—what lies beyond anti-TNF therapy?. Inflammatory bowel diseases. 2014 Feb 1;20(2):389-97.
-
Hanson ML, Hixon JA, Li W, Felber BK, Anver MR, Stewart CA, Janelsins BM, Datta SK, Shen W, McLean MH, Durum SK. Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology. 2014 Jan 31;146(1):210-21.
-
Le Saout C, Hasley RB, Imamichi H, Tcheung L, Hu Z, Luckey MA, Park JH, Durum SK, Smith M, Rupert AW, Sneller MC. Chronic exposure to type-I IFN under lymphopenic conditions alters CD4 T cell homeostasis. PLoS pathogens. 2014 Mar 6;10(3):e1003976.
